Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy
Withdrawn · Phase 4 · NCT04080076
Conditions: Renal Disease
At a glance
- Research payments reported, 2025
- $170,700
- U.S. investigators named
- 1
- Sites paid
- 1
About the trial
- Sponsor
- NephroNet, Inc. (with Mallinckrodt)
- Tested
- Acthar 80 UNT/ML Injectable Solution (drug), Oral Tab Tacrolimus (drug)
- Dates
- Started 2019-01-12; completion 2024-09-06
- Results posted
- Not yet
Treatment with combination ACTHar gel and Tacrolimus therapy or ACTHar gel therapy alone in lowering urinary protein to creatinine (UP/Cr) ratios
From ClinicalTrials.gov, last updated 2022-09-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Mallinckrodt Hospital Products Inc. reported $170,700 in research payments for this study in 2025 (1 payments).
Products named: Acthar
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Nephronet Inc $170,700
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.